<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95038</article-id><article-id pub-id-type="doi">10.26442/2075-1753_2018.4.63-67</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Chromogranin A in the diagnosis of pheochromocytoma: review</article-title><trans-title-group xml:lang="ru"><trans-title>Хромогранин А в диагностике феохромоцитомы: обзор литературы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yukina</surname><given-names>M. Yu</given-names></name><name xml:lang="ru"><surname>Юкина</surname><given-names>Марина Юрьевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, вед. науч. сотр. отд. терапевтической эндокринологии</p></bio><email>endo-yukina@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Davtyan</surname><given-names>D. A</given-names></name><name xml:lang="ru"><surname>Давтян</surname><given-names>Диана Аршалуйсовна</given-names></name></name-alternatives><email>diadavtyan@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Troshina</surname><given-names>E. A</given-names></name><name xml:lang="ru"><surname>Трошина</surname><given-names>Екатерина Анатольевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>чл.-кор. РАН, д-р мед. наук, проф., зав. отд. терапевтической эндокринологии</p></bio><email>troshina@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Platonova</surname><given-names>N. M</given-names></name><name xml:lang="ru"><surname>Платонова</surname><given-names>Надежда Михайловна</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, гл. науч. сотр. отд. терапевтической эндокринологии</p></bio><email>doc-platonova@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Center of Endocrinology of the Ministry of Health of Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «НМИЦ эндокринологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2018</year></pub-date><volume>20</volume><issue>4</issue><issue-title xml:lang="en">VOL 20, NO4 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 20, №4 (2018)</issue-title><fpage>63</fpage><lpage>6</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/95038">https://consilium.orscience.ru/2075-1753/article/view/95038</self-uri><abstract xml:lang="en"><p>Pheochromocytoma is a tumor of neuroectodermal origin, which arises from chromaffin cells of the sympatho-adrenal system of the adrenal or extra-аdrenal localization, secreting an excessive amount of catecholamines, and accompanies with the syndrome of hypertension of varying degrees of severity and diverse metabolic disorders. In addition to the synthesis and secretion of catecholamines, these tumors are able to produce a variety of biologically active peptides, including chromogranin A (neuroendocrine secretory protein), which, along with other laboratory tests, can help in the diagnosis of pheochromocytoma.</p></abstract><trans-abstract xml:lang="ru"><p>Феохромоцитома - это опухоль нейроэктодермального происхождения, которая возникает из хромаффинных клеток симпатоадреналовой системы надпочечниковой или вненадпочечниковой локализации, секретирующая избыточное количество катехоламинов, протекающая с синдромом гипертензии разной степени выраженности и многообразными метаболическими расстройствами. Помимо синтеза и секреции катехоламинов эти опухоли способны вырабатывать разные биологически активные пептиды, в том числе и хромогранин А (нейроэндокринный секреторный протеин), который, наряду с другими лабораторными тестами, может помочь в диагностике феохромоцитомы.</p></trans-abstract><kwd-group xml:lang="en"><kwd>review</kwd><kwd>pheochromocytoma</kwd><kwd>paraganglioma</kwd><kwd>chromogranin A</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>обзор</kwd><kwd>феохромоцитома</kwd><kwd>параганглиома</kwd><kwd>хромогранин А</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Tischler A.S. Molecular and cellular biology of pheochromocytomas and extra-adrenal paragangliomas. Endocr Pathol 2006; 17: 321-8.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Lenders J.WM, Quan-Yang Duh, Eisenhofer G et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99 (6): 1915-42.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Eisenhofer G, Pacak K, Huynh T.T et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 2011; 18 (1): 97-111.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Därr R, Lenders J.W.M, Hofbauer L.C et al. Pheochromocytoma: Update on Disease Management. Ther Adv in Endo and Metab 2012; 3 (1): 11-26.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Gunawardane K.P.T, Grossman A. The clinical genetics of phaeochromocytomа and paraganglioma. Arch Endocrinol Metab 2017; 61 (5): 490-500.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Martucci V.L, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer 2014; 38 (1): 7-41.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Chen H, Sippel R.S, O'Dorisio M.S et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010; 39: 775-83.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>McNeil A.R, Blok B.H, Koelmeyer T.D et al. Phaeochromocytomas discovered during coronial, autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000; 30: 648-52.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Mannelli M, Lenders J.W.M, Pacak K et al. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab 2012; 26: 507-15.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Omura M, Saito J, Yamaguchi K et al. Prospective study on the prevalence of secondary, hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193-202.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Tucker M.E. Endocrine Society first to address rare adrenal-tumor care. Medscape Medical News 2014; June 5.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Chen Y, Xiao H, Zhou X et al. Accuracy of plasma free metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review and meta-analysis. Endocr Pract 2017; Jul 13.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Lenders J.W, Pacak K, Walther M.M et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287 (11): 1427-34.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>de Jong W.H, Eisenhofer G, Post W.J et al. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin Endocrinol Metab 2009; 94 (8): 2841-9.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Algeciras-Schimnich A, Preissner C.M, Young W.F et al. Plasma chromogranin a or urine fractionated metanephrines, follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008; 93 (1): 91-5.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Tasiemski A, Hammad H, Vandenbulcke F et al. Presence of chromogranin-derived antimicrobial peptides in plasma during, coronary artery bypass surgery and evidence of an immune origin of these peptides. Blood 2002; 100: 553-9.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Helle K.B. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 2004; 79: 769-94.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Banks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965; 97: 40C-1C.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Lee R.W, Huttner W.B. Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. J Biol Chem 1983; 258: 11326-34.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Rosa P, Hille A, Lee R.W et al. Secretogranins I and II: two tyrosine-sulfated secretory proteins common to a variety of cells secreting peptides by the regulated pathway. J Cell Biol 1985; 101: 1999-2011.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Guérin M, Guillemot J, Thouënnon E et al. Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma. Regul Pept 2010; 165 (1): 21-9.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>https://www.alpco.com/chromoa-chromogranin-a-elisa</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>d'Herbomez M, Do Cao C, Vezzosi D et al. Sep, groupe des tumeurs endocrines (GTE France). Chromogranin A assay in clinical practice. Ann Endocrinol (Paris) 2010; 71 (4): 274-80.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Campana D, Nori F, Piscitelli L et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25: 967-73.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Adolf K, Wagner L, Bergh A et al. Secretagogin is a new neuroendocrine marker in the human prostate. Prostate 2007; 67: 472-84.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Hsiao R.J, Parmer R.J, Takiyyuddin M.A, O'Connor D.T. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore). 1991; 70 (1): 33-45.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>d'Herbomez M, Forzy G, Bauters C et al. An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol 2007; 156 (5): 569-75.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Giovanella L, Ceriani L, Balerna M et al. Diagnostic value of serum chromogranin-A combined with MIBG scintigraphy inpatients with adrenal incidentalomas. Q J Nucl Med Mol Imaging 2008; 52 (1): 84-8.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Glinicki P, Jeske W, Bednarek-Papierska L et al. Chromogranin A (CgA) in adrenal tumours. Endokrynol Pol 2013; 64 (5): 358-62.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Guillemot J, Guérin M, Thouënnon E et al. Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma. PLoS One 2014; 9 (2): e88698.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Bílek R, Zelinka T, Vlček P et al. Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma. Physiol Res 2017; 66 (Suppl. 3): S397-S408.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Pregun I, Herszényi L, Juhász M et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84 (1): 22-8.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Hsiao R.J, Mezger M.S, O'Connor D.T. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990; 37 (3): 955-64.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Pieroni M, Corti A, Tota B et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007; 28 (9): 1117-27.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Di Comite G, Rossi C.M., Marinosci A et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. J Leukoc Biol 2009; 85 (1): 81-7.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Valeur J, Milde A.M, Helle K.B, Berstad A. Low serum chromogranin A in patients with self-reported food hypersensitivity. Scand J Gastroenterol 2008; 43 (11): 1403-4.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Fossmark R, Jianu C.S, Martinsen T.C et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008; 43 (1): 20-4.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Ardill J.E, O'Dorisio T.M. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin North Am 2010; 39 (4): 777-90.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Srivastava A, Padilla O, Fischer-Colbrie R. et al. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids.Am J Surg Pathol 2004; 28 (10): 1371-8.</mixed-citation></ref></ref-list></back></article>
